Back to Results
First PageMeta Content



PRESS RELEASE DYADIC NETHERLANDS ENTERS INTO R&D COLLABORATION WITH SANOFI PASTEUR AND ENGEN BIO Sanofi Pasteur to Fund Research Utilizing Dyadic’s C1 Platform Technology For Certain Vaccine Applications JUPITER, Fla.
Add to Reading List

Document Date: 2013-07-12 03:34:12


Open Document

File Size: 181,88 KB

Share Result on Facebook

City

Redwood City / Lyon / WAGENINGEN / /

Company

Dyadic Netherlands / Dyadic International Inc. / Dyadic Netherland / Dyadic Nederland B.V. / EnGen Bio Inc. / SANOFI PASTEUR / Contact Dyadic International Inc. / /

Country

France / Netherlands / /

/

Event

Business Partnership / /

IndustryTerm

stage biopharmaceutical / certain vaccine applications / biotechnology / owned subsidiary / protein products / biopharmaceutical applications / manufacturing / development subsidiary / /

Person

Mark Alfenito / Mark Emalfarb / /

/

Position

President and CEO / President and Chief Executive Officer / General Manager / Dr. ir / Adam J. Morgan Vice President General Counsel / /

Product

C1 / /

ProvinceOrState

Florida / California / /

Technology

Adam / biofuels / biotechnology / C1 Platform Technology / C1 technology / /

URL

www.sanofipasteur.com / www.sanofipasteur.us / www.dyadic.com / www.engenbio.com / www.dyadic.nl / /